Skip to main content

Epoch Said Strong Q2 Sales, Lower R&D Helped Keep Net Loss Static

NEW YORK, July 30 - Epoch Biosciences today said strong second-quarter  product sales helped drive total revenue, while a slight decrease in R&D spending helped keep net loss unchanged.


For the three-month period ended June 30, Epoch said total revenue climbed to $2.5 million from $1.8 million on year ago. Product sales, which grew to $1.7 million from $1.1 million in the year-ago period, led the growth followed by a modest growth in licensing fees and royalties, the firm said.


R&D spending in the current second quarter, meanwhile, fell to $1.1 million from $1.2 million year over year, according to Epoch. Spending on sales and marketing, however, increased to $319,000 in the second quarter 2002 from $106,000 in the same period one year ago.


As a result, Epoch said second-quarter net loss was virtually unchanged year over year at $1.2 million, or $.05 per share.


The company said it had roughly $5 million in cash and cash equivalents as of June 30. It had about $8.4 during the same period one year ago.


Click here for more information.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.